


Jeffery et al. Supplementary Materials

Table A: Acute viral respiratory illness diagnosis codes.....	2
Figure A: Cohort flow chart (main cohort)	3
Table B: Data underlying Manuscript Figure 1 (cohort comparison, main cohort).....	4
Table C: Complete regression results (main cohort).....	5
Figure B: Cohort flow diagram (falsification cohort).....	8
Table D: Cohort characteristics. Values are numbers (percentages) except where specified.....	9
Figure C: Cohort comparison charts (falsification cohort)	11
Table E: Data underlying Figure 3 (cohort comparison, falsification cohort)	13
Table F: Complete regression results (falsification cohort).....	14

Table A: Acute viral respiratory illness diagnosis codes

Illness	ICD10 codes
SARS	B97.21, B97.29
Pneumonia (viral)	J12*, J16, J16.8, J18*, J84.11, J84.111
Bronchitis	J20*, J40
Lower respiratory infection	J22, J44.0, J47.0
Influenza	J09*, J10*, J11*

Figure A: Cohort flow chart (main cohort)



* Influenza season dates for 2018/19, according to CDC

Table B: Data underlying Manuscript Figure 1 (cohort comparison, main cohort)

Label	ACEi or ARB vs. other					ACEi vs. ARB				
	Risk ratio	95% confidence interval		unadjusted p value*	adjusted p value†	Risk ratio	95% confidence interval		unadjusted p value*	adjusted p value†
Female	0.94	0.94	0.95	<0.001	<0.001	0.87	0.86	0.88	<0.001	<0.001
Commercial	1.43	1.40	1.46	<0.001	<0.001	1.07	1.05	1.09	<0.001	<0.001
New England	0.88	0.85	0.92	<0.001	<0.001	1.14	1.08	1.19	<0.001	<0.001
Mid Atlantic	0.87	0.84	0.89	<0.001	<0.001	0.87	0.84	0.90	<0.001	<0.001
South Atlantic	1.01	1.00	1.02	0.066	0.724	0.90	0.89	0.91	<0.001	<0.001
East North Central	0.91	0.89	0.93	<0.001	<0.001	1.18	1.15	1.22	<0.001	<0.001
East South Central	0.99	0.96	1.02	0.383	1.000	1.00	0.97	1.04	0.857	1.000
West North Central	0.92	0.89	0.95	<0.001	<0.001	1.34	1.29	1.40	<0.001	<0.001
West South Central	1.18	1.16	1.21	<0.001	<0.001	1.06	1.03	1.08	<0.001	<0.001
Mountain	1.24	1.19	1.29	<0.001	<0.001	1.19	1.13	1.25	<0.001	<0.001
Pacific	1.13	1.08	1.19	<0.001	<0.001	0.81	0.76	0.86	<0.001	<0.001
Unknown region	0.99	0.62	1.58	0.966	1.000	1.12	0.63	1.98	0.704	1.000
<25	0.83	0.64	1.09	0.181	1.000	2.49	1.69	3.66	<0.001	<0.001
25 to 44	1.06	1.01	1.10	0.020	0.245	1.41	1.34	1.49	<0.001	<0.001
45 to 64	1.21	1.19	1.23	<0.001	<0.001	1.18	1.16	1.20	<0.001	<0.001
65 to 74	1.11	1.10	1.12	<0.001	<0.001	0.98	0.96	0.99	0.002	0.030
75 to 85	0.93	0.92	0.94	<0.001	<0.001	0.89	0.87	0.90	<0.001	<0.001
85+	0.65	0.63	0.66	<0.001	<0.001	0.86	0.84	0.89	<0.001	<0.001
White	0.97	0.96	0.97	<0.001	<0.001	1.12	1.11	1.12	<0.001	<0.001
Black	0.90	0.88	0.92	<0.001	<0.001	0.87	0.85	0.89	<0.001	<0.001
Hispanic	1.41	1.38	1.45	<0.001	<0.001	0.75	0.73	0.77	<0.001	<0.001
Asian	1.16	1.09	1.23	<0.001	<0.001	0.50	0.47	0.54	<0.001	<0.001
Unknown/other race/ethnicity	1.00	0.97	1.02	0.684	1.000	1.06	1.03	1.09	<0.001	<0.001
Uncomplicated hypertension	1.06	1.05	1.06	<0.001	<0.001	1.02	1.02	1.03	<0.001	<0.001
Complicated hypertension	0.72	0.70	0.73	<0.001	<0.001	0.84	0.82	0.86	<0.001	<0.001
No diabetes	0.90	0.90	0.91	<0.001	<0.001	0.98	0.97	0.99	<0.001	<0.001
Diabetes without CC	1.43	1.40	1.46	<0.001	<0.001	1.07	1.04	1.09	<0.001	<0.001
Diabetes with CC	1.08	1.06	1.09	<0.001	<0.001	1.01	0.99	1.03	0.266	1.000
Coronary artery disease	0.79	0.78	0.80	<0.001	<0.001	1.05	1.03	1.07	<0.001	<0.001
Congestive heart failure	0.65	0.64	0.66	<0.001	<0.001	0.98	0.96	1.00	0.121	1.000
Chronic pulmonary disease	0.80	0.79	0.80	<0.001	<0.001	0.97	0.95	0.98	<0.001	<0.001
Renal failure	0.64	0.63	0.65	<0.001	<0.001	0.85	0.83	0.87	<0.001	<0.001
Liver failure	0.65	0.62	0.68	<0.001	<0.001	1.14	1.08	1.21	<0.001	<0.001
Metastatic cancer	0.64	0.61	0.68	<0.001	<0.001	1.16	1.07	1.25	<0.001	0.002
Lymphoma	0.60	0.56	0.65	<0.001	<0.001	0.93	0.84	1.03	0.172	1.000
Solid tumor (non-metastatic)	0.73	0.71	0.75	<0.001	<0.001	1.03	0.99	1.07	0.097	0.971

* P value is for the Pearson chi-squared test with one degree of freedom

† Adjusted p-values calculated following the Holm sequentially rejective procedure, treating all comparisons in this table as a single family of comparisons.

Table C: Complete regression results (main cohort)

	Outcome/dependent variable				
	Inpatient stay	ICU or CCU use	Acute respiratory distress	ARDS	Died same or next calendar month
Other HTN meds only	ref.	ref.	ref.	ref.	ref.
ACEi	0.938*** (0.910,0.967)	0.940** (0.902,0.979)	0.93 (0.839,1.031)	0.963 (0.809,1.145)	0.785*** (0.745,0.827)
ARB	0.816*** (0.791,0.842)	0.823*** (0.789,0.859)	0.783*** (0.703,0.872)	0.705*** (0.583,0.852)	0.643*** (0.608,0.680)
Female=1	0.901*** (0.878,0.925)	0.852*** (0.823,0.883)	0.902* (0.826,0.984)	0.933 (0.803,1.085)	0.803*** (0.768,0.839)
<25	1.602 (0.964,2.661)	2.085* (1.101,3.949)	5.420** (1.661,17.684)	2.639 (0.364,19.127)	1.148 (0.370,3.562)
25-44	0.716*** (0.639,0.802)	0.738*** (0.630,0.863)	0.745 (0.486,1.143)	0.817 (0.437,1.528)	0.553*** (0.402,0.760)
45-64	ref.	ref.	ref.	ref.	ref.
65-74	0.983 (0.943,1.025)	0.966 (0.914,1.021)	0.863* (0.754,0.987)	0.893 (0.707,1.129)	1.333*** (1.222,1.454)
75+	1.265*** (1.214,1.319)	1.062* (1.006,1.122)	0.935 (0.819,1.068)	0.899 (0.712,1.136)	2.632*** (2.423,2.860)
Medicare Advantage	ref.	ref.	ref.	ref.	ref.
Commercial	0.566*** (0.537,0.598)	0.596*** (0.553,0.642)	0.520*** (0.424,0.637)	0.792 (0.579,1.082)	0.574*** (0.510,0.646)
Unk/Other Census Region	1.076 (0.451,2.564)	2.319 (0.979,5.494)			1.598 (0.603,4.237)
New England	ref.	ref.	ref.	ref.	ref.
Mid Atlantic	0.997 (0.928,1.071)	1.082 (0.976,1.200)	1.356* (1.062,1.733)	2.526*** (1.608,3.970)	1.033 (0.926,1.153)
South Atlantic	0.904** (0.849,0.963)	1.250*** (1.142,1.368)	1.223 (0.981,1.525)	1.567* (1.022,2.405)	0.737*** (0.669,0.812)
E North Central	1.081* (1.010,1.156)	1.291*** (1.172,1.422)	0.977 (0.766,1.246)	1.274 (0.803,2.019)	0.932 (0.840,1.034)
E South Central	0.908* (0.842,0.980)	1.122* (1.007,1.250)	1.235 (0.949,1.606)	0.904 (0.529,1.546)	0.802*** (0.710,0.907)
W North Central	1.167*** (1.082,1.258)	1.460*** (1.314,1.623)	1.192 (0.915,1.552)	1.457 (0.886,2.394)	0.956 (0.849,1.078)
W South Central	0.978 (0.912,1.048)	1.267*** (1.148,1.399)	1.285* (1.010,1.636)	1.426 (0.893,2.277)	0.773*** (0.691,0.864)
Mountain	0.679*** (0.615,0.749)	0.951 (0.831,1.090)	0.628* (0.425,0.927)	0.878 (0.450,1.713)	0.724*** (0.618,0.848)
Pacific	1.027	1.526***	1.018	1.703	0.884

	Outcome/dependent variable				
	Inpatient stay	ICU or CCU use	Acute respiratory distress	ARDS	Died same or next calendar month
Unk/other race/ethnicity	(0.932,1.131)	(1.340,1.738)	(0.711,1.456)	(0.935,3.102)	(0.754,1.036)
	0.948*	0.992	0.886	0.923	0.991
	(0.909,0.988)	(0.938,1.050)	(0.768,1.023)	(0.724,1.177)	(0.923,1.065)
White	ref.	ref.	ref.	ref.	ref.
Black	1.025	0.993	0.99	0.99	0.977
	(0.989,1.062)	(0.946,1.043)	(0.880,1.114)	(0.810,1.210)	(0.918,1.040)
Hispanic	0.781***	0.981	0.995	0.793	0.727***
	(0.745,0.818)	(0.925,1.041)	(0.860,1.153)	(0.600,1.047)	(0.670,0.789)
Asian	0.818***	0.855*	0.775	0.477	0.807*
	(0.741,0.904)	(0.746,0.980)	(0.530,1.135)	(0.226,1.009)	(0.680,0.958)
No diabetes	ref.	ref.	ref.	ref.	ref.
Diabetes without CC	1.026	1.062*	1.011	0.949	0.997
	(0.987,1.067)	(1.008,1.120)	(0.883,1.156)	(0.747,1.207)	(0.929,1.069)
Diabetes with CC	1.210***	1.182***	1.032	1.216*	1.132***
	(1.174,1.248)	(1.135,1.231)	(0.931,1.143)	(1.020,1.450)	(1.076,1.191)
Uncomp hypertension	ref.	ref.	ref.	ref.	ref.
Comp hypertension	1.218***	1.103***	1.063	1.082	1.032
	(1.172,1.266)	(1.049,1.160)	(0.938,1.204)	(0.881,1.329)	(0.971,1.097)
Coronary art dis	1.221***	1.308***	1.182***	1.018	1.378***
	(1.185,1.257)	(1.258,1.360)	(1.072,1.303)	(0.857,1.209)	(1.313,1.446)
Congest heart fail	2.355***	2.787***	2.838***	2.922***	2.774***
	(2.284,2.429)	(2.674,2.905)	(2.551,3.158)	(2.416,3.534)	(2.635,2.919)
Chronic pulmonary	1.948***	1.741***	2.287***	1.686***	1.073**
	(1.897,1.999)	(1.680,1.805)	(2.079,2.516)	(1.437,1.978)	(1.025,1.123)
Renal failure	1.160***	1.179***	1.108	1.215	1.485***
	(1.118,1.202)	(1.124,1.236)	(0.985,1.245)	(0.992,1.487)	(1.403,1.571)
Liver failure	1.435***	1.496***	1.345**	1.526**	2.626***
	(1.350,1.525)	(1.389,1.612)	(1.126,1.606)	(1.139,2.043)	(2.420,2.848)
Metastatic cancer	2.173***	2.015***	1.675***	1.608*	3.563***
	(2.002,2.359)	(1.825,2.225)	(1.333,2.105)	(1.052,2.457)	(3.214,3.949)
Lymphoma	1.630***	1.575***	1.395*	1.427	1.591***
	(1.473,1.804)	(1.392,1.783)	(1.038,1.875)	(0.860,2.365)	(1.378,1.837)
Non-metastatic solid tumor	1.346***	1.341***	1.346***	1.046	1.896***
	(1.281,1.414)	(1.259,1.429)	(1.154,1.569)	(0.785,1.395)	(1.766,2.036)
Constant	0.086***	0.030***	0.004***	0.001***	0.018***
	(0.080,0.093)	(0.027,0.034)	(0.003,0.005)	(0.001,0.002)	(0.016,0.020)
Number of episodes	236,843	236,843	236,768	236,768	236,433
Number of unique patients	202,629	202,629	202,569	202,569	202,289

	Outcome/dependent variable				
	Inpatient stay	ICU or CCU use	Acute respiratory distress	ARDS	Died same or next calendar month
p (for regression)	<0.001	<0.001	<0.001	<0.001	<0.001
Pseudo R ²	0.105	0.096	0.074	0.053	0.151

Odds ratios presented after logistic regression

* p<0.05, ** p<0.01, *** p<0.001

Figure B: Cohort flow diagram (falsification cohort)




Table D: Cohort characteristics. Values are numbers (percentages) except where specified

	Included cohort				Total included cohort
	No HTN meds	Other HTN meds only	ACEi	ARB	
Female	10,774 (56.4)	20,857 (65.9)	20,982 (53.8)	20,860 (63.9)	62,699 (60.7)
Insurance type					
Medicare Advantage	12,553 (65.8)	24,312 (76.8)	28,014 (71.8)	24,039 (73.6)	76,365 (73.9)
Commercial	6,534 (34.2)	7,347 (23.2)	11,012 (28.2)	8,629 (26.4)	26,988 (26.1)
Census Division					
New England	634 (3.3)	1,371 (4.3)	1,644 (4.2)	1,128 (3.5)	4,143 (4.0)
Mid Atlantic	1,375 (7.2)	2,656 (8.4)	2,809 (7.2)	2,737 (8.4)	8,202 (7.9)
South Atlantic	5,398 (28.3)	9,894 (31.3)	11,445 (29.3)	10,805 (33.1)	32,144 (31.1)
East North Central	3,789 (19.9)	6,893 (21.8)	8,449 (21.6)	6,555 (20.1)	21,897 (21.2)
East South Central	921 (4.8)	1,744 (5.5)	2,009 (5.1)	1,892 (5.8)	5,645 (5.5)
West North Central	2,915 (15.3)	3,737 (11.8)	4,901 (12.6)	3,094 (9.5)	11,732 (11.4)
West South Central	1,788 (9.4)	2,361 (7.5)	3,556 (9.1)	3,004 (9.2)	8,921 (8.6)
Mountain	1,453 (7.6)	1,830 (5.8)	2,746 (7.0)	2,164 (6.6)	6,740 (6.5)
Pacific and Unknown/other	814 (4.2)	1,173 (3.7)	1,467 (3.7)	1,289 (3.9)	3,929 (3.7)
Age (categories)					
<44	210 (1.1)	176 (0.6)	224 (0.6)	108 (0.3)	508 (0.5)
45-64	6,442 (33.8)	8,253 (26.1)	11,689 (30.0)	8,547 (26.2)	28,489 (27.6)
65-74	7,561 (39.6)	13,003 (41.1)	16,792 (43.0)	14,355 (43.9)	44,150 (42.7)
75-84	4,191 (22.0)	8,723 (27.6)	9,151 (23.4)	8,516 (26.1)	26,390 (25.5)
85+	683 (3.6)	1,504 (4.8)	1,170 (3.0)	1,142 (3.5)	3,816 (3.7)
Race/ethnicity					
White	14,327 (75.1)	23,182 (73.2)	29,474 (75.5)	23,126 (70.8)	75,782 (73.3)
Black	2,007 (10.5)	4,187 (13.2)	4,205 (10.8)	4,196 (12.8)	12,588 (12.2)
Hispanic	1,258 (6.6)	1,709 (5.4)	2,432 (6.2)	2,429 (7.4)	6,570 (6.4)
Asian	267 (1.4)	430 (1.4)	395 (1.0)	659 (2.0)	1,484 (1.4)
Unknown/other	1,228 (6.4)	2,151 (6.8)	2,520 (6.5)	2,258 (6.9)	6,929 (6.7)
Comorbidities					
Uncomp hypertension	17,622 (92.3)	28,248 (89.2)	35,232 (90.3)	29,088 (89.0)	92,568 (89.6)
Comp hypertension	1,465 (7.7)	3,411 (10.8)	3,794 (9.7)	3,580 (11.0)	10,785 (10.4)
No diabetes	15,047 (78.8)	25,181 (79.5)	26,412 (67.7)	22,207 (68.0)	73,800 (71.4)
Diabetes without CC	2,263 (11.9)	3,377 (10.7)	6,820 (17.5)	5,563 (17.0)	15,760 (15.2)
Diabetes with CC	1,777 (9.3)	3,101 (9.8)	5,794 (14.8)	4,898 (15.0)	13,793 (13.3)
Coronary artery disease	2,401 (12.6)	5,712 (18.0)	6,483 (16.6)	5,198 (15.9)	17,393 (16.8)
Congestive heart failure	659 (3.5)	2,265 (7.2)	2,201 (5.6)	1,981 (6.1)	6,447 (6.2)
Chronic pulmonary disease	2,940 (15.4)	5,607 (17.7)	5,290 (13.6)	5,225 (16.0)	16,122 (15.6)
Renal failure	1,431 (7.5)	3,612 (11.4)	3,726 (9.5)	3,568 (10.9)	10,906 (10.6)
Liver failure	314 (1.6)	596 (1.9)	554 (1.4)	477 (1.5)	1,627 (1.6)
Metastatic cancer	89 (0.5)	126 (0.4)	113 (0.3)	109 (0.3)	348 (0.3)
Lymphoma	89 (0.5)	130 (0.4)	130 (0.3)	118 (0.4)	378 (0.4)

	Included cohort				Total included cohort
	No HTN meds	Other HTN meds only	ACEi	ARB	
Non-metastatic solid tumor	678 (3.6)	1,150 (3.6)	1,235 (3.2)	1,148 (3.5)	3,533 (3.4)
Rheumatoid/arthritis/ collagen disorder	1,052 (5.5)	2,080 (6.6)	1,933 (5.0)	1,823 (5.6)	5,836 (5.6)
Episode length (days)					
Mean (sd)	3.7 (10.8)	3.7 (4.0)	3.5 (2.7)	3.6 (3.0)	3.6 (3.3)
Median (25th, 75th percentiles)	3 (2, 4)	3 (2, 4)	3 (2, 4)	3 (2, 4)	3 (2, 4)
Number of days of healthcare with hypertension diagnosis, 180 days before index date					
Mean (sd)	2.9 (2.8)	3.8 (3.4)	3.7 (3.0)	3.9 (2.9)	3.8 (3.1)
Median (25th, 75th percentiles)	2 (1, 3)	3 (2, 4)	3 (2, 4)	3 (2, 5)	3 (2, 4)
N (episodes)	19,087	31,659	39,026	32,668	103,353
N (unique people)	18,099	29,124	35,711	29,799	93,714
* This group is not included in analyses; characteristics are presented for context					
HTN hypertension; ACEi angiotensin-converting enzyme inhibitors; ARB angiotensin receptor blockers; CC Complicating conditions; sd standard deviation					

Figure C: Cohort comparison charts (falsification cohort)

Rate ratios comparing baseline characteristics of Figure Ca people taking ACEis or ARBs to people taking other HTN medications and Figure Cb people taking ACEis to people taking ARBs. 95% confidence intervals are not adjusted for multiple comparisons

Figure Ca: The comparisons for six characteristics are not statistically significant after multiple comparison adjustment: East North Central (unadjusted $p=0.002$; adjusted $p=0.07$), West North Central (unadjusted $p=0.002$; adjusted $p=0.07$), uncomplicated hypertension (unadjusted $p=0.02$; adjusted $p=0.39$), complicated hypertension (unadjusted $p=0.02$; adjusted $p=0.39$), metastatic cancer (unadjusted $p=0.02$; adjusted $p=0.48$), solid tumor no mets (unadjusted $p=0.01$; adjusted $p=0.31$)




Figure Cb: The comparisons for six characteristics are not statistically significant after multiple comparison adjustment: solid tumor no mets (unadjusted $p=0.01$; adjusted $p=0.26$), coronary artery disease (unadjusted $p=0.01$; adjusted $p=0.31$), age 65 to 74 (unadjusted $p=0.01$; adjusted $p=0.35$), unknown/other race (unadjusted $p=0.02$; adjusted $p=0.36$), congestive heart failure (unadjusted $p=0.02$; adjusted $p=0.36$), Mountain (unadjusted $p=0.03$; adjusted $p=0.56$)




Table E: Data underlying Figure C (cohort comparison, falsification cohort)

	ACEi or ARB vs other					ACEi vs ARB				
	Risk ratio	95% confidence interval		unadjusted p value*	adjusted p value†	Risk ratio	95% confidence interval		unadjusted p value*	adjusted p value†
Female	.8859	.8770	.8948	<0.001	<0.001	.8420	.8317	.8524	<0.001	<0.001
Commercial	1.1805	1.1533	1.2084	<0.001	<0.001	1.0683	1.0429	1.0942	<0.001	<0.001
New England	.8928	.8380	.9512	<0.001	0.014	1.2200	1.1326	1.3142	<0.001	<0.001
Mid Atlantic	.9221	.8821	.9639	<0.001	0.011	.8591	.8168	.9036	<0.001	<0.001
South Atlantic	.9931	.9737	1.0128	0.487	1.000	.8867	.8675	.9062	<0.001	<0.001
East North Central	.9612	.9372	.9858	0.002	0.066	1.0789	1.0484	1.1104	<0.001	<0.001
East South Central	.9877	.9350	1.0435	0.660	1.000	.8888	.8362	.9448	<0.001	0.005
West North Central	.9447	.9109	.9799	0.002	0.067	1.3260	1.2707	1.3836	<0.001	<0.001
West South Central	1.2269	1.1728	1.2836	<0.001	<0.001	.9909	.9461	1.0379	0.699	1.000
Mountain	1.1848	1.1247	1.2481	<0.001	<0.001	1.0622	1.0060	1.1216	0.030	0.562
Pacific	1.0325	.9654	1.1043	0.351	1.000	.9531	.8854	1.0260	0.202	1.000
Unknown region	2.2079	.8453	5.7670	0.097	1.000	.9068	.4138	1.9871	0.807	1.000
25 to 44	.8377	.6979	1.0056	0.057	1.000	1.7362	1.3806	2.1833	<0.001	<0.001
45 to 64	1.0827	1.0593	1.1067	<0.001	<0.001	1.1448	1.1180	1.1723	<0.001	<0.001
65 to 74	1.0578	1.0414	1.0744	<0.001	<0.001	.9792	.9629	.9957	0.014	0.347
75 to 85	.8944	.8749	.9142	<0.001	<0.001	.8995	.8768	.9228	<0.001	<0.001
85+	.6788	.6370	.7234	<0.001	<0.001	.8576	.7915	.9292	<0.001	0.006
White	1.0020	.9940	1.0100	0.631	1.000	1.0669	1.0573	1.0765	<0.001	<0.001
Black	.8860	.8559	.9172	<0.001	<0.001	.8389	.8059	.8733	<0.001	<0.001
Hispanic	1.2560	1.1906	1.3251	<0.001	<0.001	.8381	.7938	.8849	<0.001	<0.001
Asian	1.0824	.9683	1.2099	0.163	1.000	.5017	.4433	.5679	<0.001	<0.001
Unknown/other race	.9809	.9339	1.0303	0.442	1.000	.9342	.8843	.9869	0.015	0.361
Uncomplicated hypertension	1.0055	1.0009	1.0101	0.018	0.392	1.0139	1.0088	1.0190	<0.001	<0.001
Complicated hypertension	.9546	.9187	.9920	0.018	0.392	.8871	.8496	.9263	<0.001	<0.001
No diabetes	.8526	.8462	.8590	<0.001	<0.001	.9956	.9856	1.0057	0.392	1.000
Diabetes without CC	1.6192	1.5625	1.6780	<0.001	<0.001	1.0262	.9937	1.0598	0.115	1.000
Diabetes with CC	1.5226	1.4662	1.5811	<0.001	<0.001	.9902	.9561	1.0256	0.583	1.000
Coronary artery disease	.9030	.8774	.9294	<0.001	<0.001	1.0440	1.0097	1.0795	0.011	0.309
Congestive heart failure	.8153	.7760	.8566	<0.001	<0.001	.9300	.8769	.9865	0.016	0.363
Chronic pulmonary disease	.8281	.8040	.8530	<0.001	<0.001	.8475	.8181	.8779	<0.001	<0.001
Renal failure	.8917	.8588	.9259	<0.001	<0.001	.8742	.8369	.9130	<0.001	<0.001
Liver failure	.7639	.6912	.8442	<0.001	<0.001	.9722	.8609	1.0978	0.649	1.000
Metastatic cancer	.7780	.6255	.9678	0.024	0.476	.8678	.6673	1.1285	0.290	1.000
Lymphoma	.8424	.6816	1.0411	0.112	1.000	.9222	.7191	1.1827	0.523	1.000
Solid tumor (non-met)	.9150	.8539	.9805	0.012	0.309	.9005	.8321	.9745	0.009	0.261

* P value is for the Pearson chi-squared test with one degree of freedom

† Adjusted p-values calculated following the Holm sequentially rejective procedure, treating all comparisons in this table as a single family of comparisons.

Table F: Complete regression results (falsification cohort)

	Any complication [†]	Died same or next calendar month
Other HTN meds only	ref.	ref.
ACEi	0.885* (0.803,0.976)	0.792 (0.595,1.053)
ARB	0.818*** (0.738,0.908)	0.643** (0.472,0.874)
Commercial	0.658*** (0.569,0.762)	0.699 (0.400,1.221)
Female=1	0.978 (0.896,1.068)	0.825 (0.635,1.072)
25-44	1.265 (0.738,2.170)	2.205 (0.291,16.723)
45-64	ref.	ref.
65-74	0.742*** (0.650,0.848)	1.505 (0.898,2.522)
75-84	0.759*** (0.655,0.880)	2.714*** (1.607,4.584)
85+	1.117 (0.904,1.381)	9.209*** (5.225,16.233)
New England	ref	ref
Mid Atlantic	1.112 (0.865,1.431)	1.042 (0.487,2.232)
South Atlantic	0.958 (0.767,1.196)	1.083 (0.551,2.130)
E North Central	1.058 (0.844,1.325)	1.291 (0.657,2.538)
E South Central	0.916 (0.693,1.211)	1.481 (0.670,3.272)
W North Central	1.002 (0.787,1.277)	1.041 (0.494,2.195)
W South Central	1.106 (0.859,1.424)	0.887 (0.387,2.031)
Mountain	1.159 (0.893,1.506)	1.319 (0.594,2.929)
Pacific	1.052 (0.781,1.419)	1.018 (0.392,2.642)
Unk race	1.022 (0.865,1.207)	1.261 (0.781,2.036)
White	ref.	ref.
Black	1.054 (0.928,1.197)	1.417 (0.997,2.014)

	Any complication [†]	Died same or next calendar month
Hispanic	0.924 (0.774,1.103)	0.968 (0.561,1.669)
Asian	0.719 (0.482,1.071)	1.763 (0.761,4.085)
Uncomp hypertension	ref.	ref.
Comp hypertension	1.014 (0.852,1.206)	0.751 (0.488,1.156)
Coronary art dis	1.201*** (1.081,1.335)	1.895*** (1.449,2.479)
Congest heart fail	1.649*** (1.440,1.888)	2.028*** (1.499,2.745)
Chronic pulmonary	1.402*** (1.270,1.548)	1.779*** (1.359,2.329)
No diabetes	ref.	ref.
Diabetes without CC	0.958 (0.849,1.081)	1.273 (0.890,1.820)
Diabetes with CC	1.276*** (1.138,1.430)	1.779*** (1.328,2.383)
Renal failure	1.132 (0.953,1.344)	1.749** (1.190,2.571)
Liver failure	1.332* (1.017,1.745)	3.498*** (1.986,6.163)
Metastatic cancer	1.423 (0.820,2.469)	11.831*** (6.001,23.325)
Lymphoma	1.880* (1.136,3.111)	1.176 (0.297,4.662)
Non-metastatic solid tumor	1.105 (0.897,1.363)	1.011 (0.601,1.702)
Rheumatoid/arthritis/collagen disorder	1.203* (1.024,1.414)	1.141 (0.692,1.882)
Constant	0.029*** (0.022,0.037)	0.001*** (0.000,0.002)
Number of surgeries	103,322	103,152
Number of unique patients	93,686	93,533
p (for regression)	<0.001	<0.001
pseudo R ²	0.014	0.099

Odds ratios presented after logistic regression

* p<0.05, ** p<0.01, *** p<0.001

[†] Acute myocardial infarction or sepsis within 7 days of surgery; surgical site complication or pulmonary embolism within 30 days; and/or mechanical complication or periprosthetic wound infection/complication within 90 days